Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

IL-33 mediated mast cell activation promotes gastric cancer through macrophage mobilization

Eissman, Moritz F, Dijkstra, Christine, Jarnicki, Andrew, Phesse, Toby ORCID:, Brunnberg, Jamina, Poh, Ashleigh R, Etemadi, Nima, Tsantikos, Evelyn, Thiem, Stefan, Huntington, Nicholas H, Hibbs, Margaret L, Boussioutas, Alex, Grimbaldeston, Michele A, Buchert, Michael, O'Donoghue, Robert J J, Masson, Frederick and Ernst, Matthias 2019. IL-33 mediated mast cell activation promotes gastric cancer through macrophage mobilization. Nature Communications 10 , 2735. 10.1038/s41467-019-10676-1

[thumbnail of Eissmann et al NCOMMS-18-00591C_Supplementary Info and Data.docx.pdf]
PDF - Supplemental Material
Download (11MB) | Preview
[thumbnail of s41467-019-10676-1.pdf]
PDF - Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview


The contribution of mast cells in the microenvironment of solid malignancies remains controversial. Here we functionally assess the impact of tumor-adjacent, submucosal mast cell accumulation in murine and human intestinal-type gastric cancer. We find that genetic ablation or therapeutic inactivation of mast cells suppresses accumulation of tumor-associated macrophages, reduces tumor cell proliferation and angiogenesis, and diminishes tumor burden. Mast cells are activated by interleukin (IL)-33, an alarmin produced by the tumor epithelium in response to the inflammatory cytokine IL-11, which is required for the growth of gastric cancers in mice. Accordingly, ablation of the cognate IL-33 receptor St2 limits tumor growth, and reduces mast cell-dependent production and release of the macrophage-attracting factors Csf2, Ccl3, and Il6. Conversely, genetic or therapeutic macrophage depletion reduces tumor burden without affecting mast cell abundance. Therefore, tumor-derived IL-33 sustains a mast cell and macrophage-dependent signaling cascade that is amenable for the treatment of gastric cancer.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Biosciences
European Cancer Stem Cell Research Institute (ECSCRI)
Publisher: Nature Publishing Group
ISSN: 2041-1723
Date of First Compliant Deposit: 22 May 2019
Date of Acceptance: 22 May 2019
Last Modified: 11 Oct 2023 21:59

Citation Data

Cited 70 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics